2025-12-10 – Xinnate Receives FDA IND Approval for TCP-25 Enabling Pivotal Phase 2-3 STEP Study in EB
  1. Home
  2. News
  3. Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa
  4. 2025-12-10 – Xinnate Receives FDA IND Approval for TCP-25 Enabling Pivotal Phase 2-3 STEP Study in EB
© 2026 Xinnate. All rights reserved